S

    Septerna, Inc. Common Stock (SEPN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $38.15
    -0.76 (-1.95%)

    Market Cap: $1.82B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(4/8)
    Avg Surprise
    -115.70%
    Streak
    3 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.63
    Range$-0.93 - $-0.22
    4 analysts
    EPS RevisionsNo revisions (7d)
    1
    1
    30d
    EPS Estimate Drift
    90d ago$-0.42+33.6%
    60d ago$-0.55+11.7%
    30d ago$-0.55+11.7%
    7d ago$-0.55+11.7%
    Current$-0.63
    Revenue Consensus
    $22M
    Range$0 - $32M
    8 analysts
    Dec 31, 2026
    EPS Consensus$0.21
    Range$0.03 - $0.36
    4 analysts
    Revenue Consensus
    $40M
    Range$-2511110 - $62M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.21---
    Sep 26EST
    		-$-0.63---
    Jun 26
    		$-0.29$-0.48+39.58%Beat+48.2%
    Mar 26
    		$-0.19N/A+56.82%Beat+61.2%
    Dec 25
    		$-0.24N/A+66.67%Beat+62.5%
    Sep 25
    		$-0.10N/A-112.66%Miss+98.8%
    Jun 25
    		$-0.56$0.93-160.22%Miss+95.6%
    Mar 25
    		$-0.49$-0.38-28.95%Miss-
    Dec 24
    		$-0.64$-0.69+6.80%Beat-
    Sep 24
    		$-8.40$-0.94-793.62%Miss-
    Jun 24
    		$-12.76$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-46.52EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-24.50%Operating Margin-62.90%
    ROE-6.34%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio4.99xQuick Ratio4.99x
    Trading Statistics
    BetaN/AAvg Volume462.19K
    52-Week High$51.1052-Week Low$11.98

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$40.81
    SMA 20$41.64
    SMA 50$37.38
    SMA 200$29.38
    EMA 10$40.35
    EMA 20$40.19
    EMA 50$37.59
    EMA 200$29.44

    MACD

    Line: 0.74Signal: 1.53Hist: -0.79

    ADX

    ADX: 21.6+DI: 23.4-DI: 27.5

    Aroon & PSAR

    Aroon Up48.0
    Aroon Down4.0
    PSAR$47.19

    Bollinger Bands

    Upper Band$47.81
    Lower Band$35.48
    %B Position2960%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    45.1

    Momentum Oscillators

    Stoch %K8.8
    Stoch %D13.8
    Williams %R-94.5
    ROC (10d)-13.7%
    Momentum-6.05
    CCI (20d)-91.8
    MFI (14d)31.4

    Volatility Measures

    ATR (14d)$2.25(5.9%)
    StdDev (20d)3.08
    Hist Vol102.1%(High)

    Volume Flow

    VWAP$38.22
    OBV42.4M
    AD Line9.1M
    CMF (20d)-0.204

    Volume Metrics

    Avg Vol (20d)475.2K
    Vol Ratio0.9x
    VWMA (20d)$43.11

    Pivot Points

    R3$42.53
    R2$41.74
    R1$40.32
    Pivot Point$39.53
    S1$38.12
    S2$37.33
    S3$35.91

    Advanced Oscillators

    TSI8.83
    Ultimate Osc34.7
    KST175.58

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$26.75M$26.52M$24.12M$21.50M$119,000$219,000$212,000$176,000$370,000$317,000$118,000$33,000
    Cost of Revenue$0$0$401,000$0$0$0N/A$0$0$0N/A$0
    Gross Profit$26.75M$26.52M$24.12M$21.50M$119,000$219,000$212,000$176,000$370,000$317,000$118,000$33,000
    Operating Expenses$43.58M$39.82M$40.14M$18.88M$29.10M$26.13M$24.93M$22.73M$18.43M$15.81M$-34,199,000$12.07M
    R&D$35.13M$29.54M$31.86M$24.26M$22.19M$19.27M$19.32M$17.83M$15.04M$13.15M$10.33M$9.28M
    SG&A$8.45M$10.29M$8.28M$7.12M$6.91M$6.86M$5.61M$4.89M$3.40M$2.65M$3.10M$2.79M
    Operating Income$-16,836,000$-13,300,000$-16,023,000$2.61M$-28,978,000$-25,910,000$-24,718,000$-22,550,000$-18,065,000$-15,490,000$34.32M$-12,040,000
    Interest Income$4.80M$5.03M$5.34M$5.57M$4.17M$4.46M$3.91M$1.90M$1.53M$1.28M$1.25M$1.10M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-12,061,000$-8,300,000$-10,726,000$8.17M$-24,838,000$-21,476,000$-20,828,000$-20,659,000$-16,550,000$-14,259,000$35.59M$-10,945,000
    Income Tax Expense$973,000$337,000$12,000$0$0$0$-564,000$-136,000$109,000$93,000$691,000$0
    Net Income$-13,034,000$-8,637,000$-10,738,000$8.17M$-24,838,000$-21,476,000$-20,668,000$-20,523,000$-16,441,000$-14,166,000$34.89M$-10,945,000
    EBITDA$-16,894,000$-13,665,000$-16,550,000$2.39M$-29,573,000$-26,506,000$-25,157,000$-22,566,000$-17,905,000$-15,294,000$-13,065,000$-12,041,000
    EBIT$-16,859,000$-13,331,000$-16,064,000$2.61M$-29,003,000$-25,938,000$-24,736,000$-22,559,000$-18,080,000$-15,538,000$-13,308,000$-12,041,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SEPN

    News

    Is Septerna (SEPN) Elevating Its Clinical Strategy With a Veteran Regulatory Leader at the Helm?

    Septerna, Inc. recently appointed Rajiv Patni, M.D., as Chief Medical Officer, bringing over 25 years of biopharmaceutical leadership experience in research, development, regulatory, and medical affairs. His track record of securing 10 regulatory approvals and leading companies later acquired could bolster investor confidence in Septerna's pipeline and clinical execution. While the appointment is seen as incrementally positive for advancing clinical milestones, the company remains unprofitable with a high price-to-sales multiple, and its current valuation might already reflect significant optimism.

    Simply Wall Street•8/25/26•
    Somewhat-Bullish

    Septerna appoints Rajiv Patni as chief medical officer By Investing.com

    Septerna, Inc. has announced the appointment of Rajiv Patni, M.D., as its new Chief Medical Officer. Dr. Patni brings over 25 years of biopharmaceutical experience, having previously held significant roles at companies like Judo Bio and Reata Pharmaceuticals. His expertise spans research, development, regulatory affairs, and medical operations, with a track record of contributing to 10 regulatory approvals.

    Investing.com Canada•8/25/26•
    Bullish

    Septerna appoints Rajiv Patni as chief medical officer

    Septerna, Inc. has announced the appointment of Rajiv Patni, M.D., as its new Chief Medical Officer. Dr. Patni brings over 25 years of experience in biopharmaceutical research and development, with a successful track record in guiding investigational medicines through regulatory approvals. He will oversee Septerna's clinical development programs for its G protein-coupled receptor drug candidates.

    Investing.com•8/25/26•
    Bullish

    Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

    Septerna, Inc., a clinical-stage biotechnology company, has announced the appointment of Rajiv Patni, M.D., as its new Chief Medical Officer. Dr. Patni brings over 25 years of experience in biopharmaceutical research and development, with a successful track record in guiding investigational medicines through regulatory approvals. His appointment is expected to be instrumental in advancing Septerna's clinical programs and pipeline targeting unmet medical needs in various therapeutic areas.

    The Manila Times•8/25/26•
    Bullish

    Septerna Appoints Rajiv Patni as Chief Medical Officer

    Septerna, a clinical-stage biotech company, has appointed Rajiv Patni, M.D., as its new Chief Medical Officer, effective August 25, 2026. Dr. Patni brings over 25 years of experience in biopharmaceutical research, development, regulatory, and medical affairs, having contributed to 10 regulatory approvals or label expansions. His appointment is expected to bolster Septerna's efforts to advance its pipeline of GPCR-targeted oral medicines for various therapeutic areas.

    Stock Titan•8/25/26•
    Neutral

    Frequently Asked Questions About SEPN

    Does SEPN pay dividends?
    Septerna, Inc. Common Stock (SEPN) does not currently pay a regular dividend.
    What is SEPN's market cap?
    Septerna, Inc. Common Stock (SEPN) has a market capitalization of $1.82B with a current stock price of $38.15.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In